Recon: Novartis licenses Arrowhead's neuromuscular drug for up to $2B; Paul Offit removed from FDA’s VRBPAC
ReconJason Scott
Biologics/ biosimilars/ vaccinesEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyUnited States